


Study **I**^2 Odds Ratio (95% Crl) **Erlotinib\_chemotherapy vs Chemotherapy** → 1.0 (0.029, 36.) 71 → 1.0 (0.00097, 9.6e+02) Pooled (pair-wise) Indirect (back-calculated) Pooled (network) → 1.7 (0.071, 38.) 0.0% **Gefitinib vs Chemotherapy** 76 0.98 (0.11, 9.0)  $\Rightarrow$  2.4e-18 (1.3e-44, 4.4e+08) 77 Pooled (pair-wise) 0.43 (0.00013, 17.) 54.5% Indirect (back-calculated) 0.65 (0.046, 9.3) Pooled (network) 0.0% 0.61 (0.047, 6.0) **Osimertinib vs Chemotherapy** 42  $\rightarrow$  2.2 (0.14, 36.)  $\rightarrow$  2.0 (0.0033, 1.7e+03) Pooled (pair-wise) Indirect (back-calculated) 0.46 (0.023, 9.0) Pooled (network) 0.0% 0.59 (0.028, 6.4) **Erlotinib vs Dacomitinib** 59 1.6 (0.42, 5.9)  $\rightarrow$  1.5 (0.0026, 8.8e+02) Pooled (pair-wise) 2.9 (0.15, 58.) Indirect (back-calculated) Pooled (network) 0.0% → 2.6 (0.24, 54.) Placebo vs Dacomitinib r6  $\Rightarrow$  2.0 (0.057, 67.) > 1.9 (0.0016, 2.0e+03) Pooled (pair-wise) Indirect (back-calculated) 0.46 (0.020, 11.) ..... Pooled (network) 0.0% 0.58 (0.028, 8.6) 0.03 30



| Study   | I^2            |  | Odds Ratio (95% Crl)  |
|---|----------------|--|---|
| Erlotinib_METi vs Erlotinib                                       |                |  |   |
| 12<br>39<br>7   |                | → → → → → → → → → → → → → → → → → → →          | 0.82 (0.23, 2.8)<br>2.2e-18 (1.6e-44, 3.1e+08)<br>2.6 (0.14, 49.)   |
| Pooled (pair–wise) Indirect (back–calculated)                     | 17.4%          | •  | 0.76 (0.0030, 16.)<br>NA  |
| Pooled (network)  | 16.1%          |  | 0.78 (0.070, 6.2)   |
| Erlotinib_antiangio vs Er   | lotinib        |  |   |
| 15<br>16<br>25<br>34<br>37  |                |  | 2.4e+11 (5.6e-07, 1.1e+29)<br>2.3e+10 (8.2e-06, 6.3e+25)<br>1.0 (0.17, 5.8)<br>0.63 (0.16, 2.4)<br>5.6e-11 (1.3e-51, 2.4e+30) |
| Pooled (pair–wise) Indirect (back–calculated) Pooled (network)    | 21.0%<br>10.6% |  | 1.4 (0.19, 7.7e+02)<br>NA<br>1.2 (0.24, 12.)  |
| Placebo vs Erlotinib  |                |  |   |
| 30<br>46<br>58<br>Pooled (pair–wise)                              | 59.5%          |  | 1.2e-18 (8.4e-45, 1.6e+08)<br>0.66 (0.034, 13.)<br>1.1e-18 (1.3e-44, 9.5e+07)<br>0.093 (4.4e-06, 1.7)                         |
| Indirect (back-calculated) Pooled (network)                       | 23.4%          | <i>☆</i> ;···································· | 0.25 (0.025, 2.5)<br>0.22 (0.016, 1.2)  |
| Rociletinib vs Erlotinib  |                |  |   |
| 53 Pooled (pair–wise) Indirect (back–calculated) Pooled (network) |                |  | 1.0 (0.027, 37.)<br>0.96 (0.00086, 1.1e+03)<br>NA<br>1.0 (0.0099, 92.)  |

